Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
low volume on HWKE
i would expect in next 6 months
INTERESTING ARTICLE
GOOD DEBT DEDUCTION HERE FOR VKIN
NICE 8% GAIN
YES AUTOS IN TOUGH SPOT FOR SURE
TO GO HIGHER I BELIEVE
AVGR keeps going lower as predicted
CHART LOOK STRONG HER FOR BNTC
LOTS OF ROOM TO GO HIGHER
I EXPECT 50% DROP FROM CURRENT SING PRICE
AWESOME STOCK FOR SURE
YOU COULD BE RIGHT
very good news for HWKE
hopefully new mgt can turn this around
great news here for SNWV
like i have said before, i hope the cydy leronlimab works, but the many pr's issued by company creates doubt in my opinion
treat the patients and let the fda make their determination if the drug is good or not
Mottlet's whole week was a blurr, so does she even know if cydy drug was injected into her as the media and dr yang are saying?
seems doubtful to me!
yes, more lack of credible info posted on cydy website
no proof, just more cydy propaganda
with all the pr's issued by cytodyn i don't see where the company announcing anything with dr. yang and cydy has done numerous pr's in the past 60 days..
see below
Blood Samples at Day 0, 3 and 7 for Severely Ill COVID-19 Patients Clearly Indicate Leronlimab Has Significantly Reduced the Cytokine Storm in All (7) Patients and All Patients Demonstrated Immunological Benefit at Both Day 3 and Day 7Press Release | 04/09/2020
Severely Ill COVID-19 Patient at Leading Southern California Medical Center Extubated Three Days After Treatment with CytoDyn’s Leronlimab; Two Moderate COVID-19 Patients Removed from External Oxygen Following One Day of Treatment with Leronlimab anPress Release | 04/09/2020
Novant Health Initiates Phase 2 COVID-19 Trial with CytoDyn’s LeronlimabPress Release | 04/07/2020
“Next Super Stock” Conference Presenters Making News: CytoDyn (OTC: CYDY) New Coronavirus Treatment Progress. NexTech AR Solutions (OTC: NEXCF): Analyst Coverage; Remote Work/Learning Acquisition, Revenue Accelerates. FaceBank Group (OTC: FBNPress Release | 04/07/2020
CytoDyn Collaborating with U.K.’s Department of Health to Provide Emergency Access to Leronlimab for Severe and Critically Ill COVID-19 PatientsPress Release | 04/07/2020
First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already ExtubatedPress Release | 04/06/2020
CytoDyn CEO Dr. Pourhassan Appearance on Fox Business Network Rescheduled to April 8 Same Time (11am PT); CytoDyn will Reveal Today the Name of the Hospital and the Physician who Treated 10 Patients During an Interview on Seattle-Affiliate of CBS News whiPress Release | 04/03/2020
CytoDyn Files Request with FDA for Preliminary Meeting for Breakthrough Therapy Designation for Leronlimab in the Treatment of CancerPress Release | 04/03/2020
CytoDyn CEO Dr. Pourhassan to Appear on Fox Business Network Friday, April 3, 2020 at 2:00 pm ET to Discuss Leronlimab Treatment of 10 Severely Ill COVID-19 Patients and Express Appreciation for a Special Hospital, Physician, and Medical Team Who Treated Press Release | 04/03/2020
Treatment with CytoDyn's Leronlimab Indicates Significant Trend Toward Immunological Restoration in Severely Ill COVID-19 PatientsPress Release | 04/02/2020
CytoDyn Files a Clinical Trial Protocol with the FDA to Treat Severely Ill COVID-19 Patients with Leronlimab where the Primary Endpoint is Mortality Rate at Two WeeksPress Release | 04/01/2020
“Next Super Stocks” in News: CYDY: Coronavirus Treatment Progress. FBNK: fuboTV ($223 million run rate) Merger = Streaming Powerhouse. NEXCF: Remote Work/Learning Acquisition, Revenues Accelerating.Press Release | 03/31/2020
CytoDyn Completes Non-dilutive $15 Million Convertible Note Financing with Conversion Rate at $4.50 Per Share without WarrantsPress Release | 03/31/2020
FDA Clears CytoDyn’s Phase 2 Randomized Trial to Treat Mild-to-Moderately Ill Coronavirus Patients with Leronlimab; Enrollment to Begin ImmediatelyPress Release | 03/31/2020
Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 PatientsPress Release | 03/30/2020
CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDAPress Release | 03/27/2020
Leronlimab Used in Seven Patients with Severe COVID-19 Demonstrated Promise with Two Intubated Patients in ICU, Removed from ICU and Extubated with Reduced Pulmonary Inflammation Press Release | 03/27/2020
Two Additional Coronavirus Patients Treated at Leading New York Hospital with CytoDyn’s Leronlimab, Bringing the Total to Four PatientsPress Release | 03/23/2020
U.S. Food and Drug Administration (FDA) Grants Emergency IND for Two Coronavirus Patients Treated in New York with CytoDyn’s LeronlimabPress Release | 03/19/2020
CytoDyn to Present at Wall Street Reporter’s NEXT SUPER STOCK - Live Stream Event on March 19, 2020Press Release | 03/18/2020
CytoDyn Files Modified IND and Protocol for Phase 2 Clinical Trial for Treatment of Patients with Coronavirus with Leronlimab (PRO 140) and Advises Correction to Press Release Issued on March 12, 2020Press Release | 03/16/2020
CytoDyn Appoints Jacob Lalezari, M.D. as Interim Chief Medical OfficerPress Release | 03/13/2020
CytoDyn’s First mTNBC Patient in Phase 1b/2 is in Remission and Oncologist Ordered Termination of Treatment with Carboplatin (chemotherapy drug) and Remains on Leronlimab Only as Monotherapy; Patient’s Testimony about Her Condition After NearlPress Release | 03/12/2020
CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus Patients with Leronlimab (PRO 140)Press Release | 03/09/2020
CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Patients with Coronavirus with Leronlimab (PRO 140)Press Release | 03/08/2020
CytoDyn Treats First Patient with Leronlimab in Phase 2 Trial for GvHD under Modified Trial ProtocolPress Release | 03/04/2020
CytoDyn Reports Remarkable Outcomes for Additional Cancer Patients in mTNBC Trial; Following an Overwhelming Community Response, CytoDyn Expects to Enroll More Than 20 Patients in its 22 Solid Tumor Cancer Trial in the Next 60 DaysPress Release | 03/02/2020
CytoDyn to Hold Conference Call for Updates on Filing Phase 2 Trial with FDA for Treatment of Coronavirus in U.S., Status of BLA, Breakthrough Therapy Designation, Basket Trial for 22 Solid Tumor Cancers and Licensing Opportunities in Several CountriesPress Release | 02/28/2020
Meet Today’s Innovators: Digital Celebrities, Augmented Reality, 3D Advertising, AR E-Commerce, and Biotech Breakthroughs in Cancer, HIV therapy (and potential coronavirus treatment)Press Release | 02/27/2020
Investment Experts discuss “Coronavirus Stocks” in an interview with Wall Street ReporterPress Release | 02/25/2020
CytoDyn Receives Institutional Review Board Approval to Initiate Phase 2 Basket Trial for 22 Solid Tumor CancersPress Release | 02/21/2020
CytoDyn Interview to Air on Bloomberg International on the RedChip Money ReportPress Release | 02/20/2020
“Digital Humans”, Augmented Reality and Biotech Breakthroughs in Cancer and HIV therapyPress Release | 02/18/2020
CytoDyn Reports Continued Positive Clinical Data on its Phase 1b/2 mTNBC and Expanded Access Studies for MBC Ahead of Breakthrough Therapy Designation Decision From the FDAPress Release | 02/14/2020
CytoDyn Signs Letter of Intent for the Joint Development and Licensing of Leronlimab in China with Longen China GroupPress Release | 02/12/2020
THE DR IN LOS ANGELES IS NOT SURE IF LERONLIMAB WORKED BUT THEY STILL RUN A TV INFOMERCIAL ON CBS FOR LERONLIMAB HELPING?
this is why the medical community has no credibility
if cydy was a private company would they be doing all these media blitzes?
the answer is, of course not!
private medical companies very rarely issue any press releases or interviews until they have had direct reply from FDA on status of drug or equipment,or device
EVEN SINCE FOX BUSINESS NEWS CHARLES PAYNE INTERVIEWED CYTODYN CEO ABOUT LERONLIMAB THE STOCK IS DOWN. CYTODYN HAD ONLY TREATED 10 PEOPLE AT THAT POINT. TO ME IT IS VERY ODD THAT CHARLES PAYNE WOULD INTERVIEW ANY COMPANY AFTER ONLY 10 PEOPLE HAD BEEN TREATED. CHARLES PAYNE OF FOX BUSINESS NEVER DISCLOSED IF HE OR FOX OWNED STOCK OF CYDY OR IF THEY HAD BEEN COMPENSATED AS IS REQUIRED WHEN INTERVIEWING PUBLIC COMPANIES.
another home made cydy video?
room rates will come down or mgt is just plain stupid to sit at 30% occupency
perhaps a news retraction should be put out by cydy right away?
would the dr. perhaps be concerned about losing his license to practice medicine in california based on participating in a non-approved fda clinical trial?
i wonder what the fda would think of a company like cydy if the stock got halted?
np stated on the Charles Payne Fox Business interview that the company had treated over 800 people for HIV, how true is that?
basically all the cydy pr's seem to now be in question?
only 1/4 actually treated vs those claimed by cydy mgt.??
is that not misstating material events?
great infp on cydy and again the company mgt is grossly misstating material events
FOR THE RECORD BORIS JOHNSON WAS NOT TREATED WITH CYDY'S LERONLIMAB
he is out of ICU
yes, red crayons like the color of the cydy stock in april
can we get more of FOX NEWS HOST Charles Payne to Prop up CYTODYN?
LOL
L.A. Physician States EVERY Covid-19 Patient He Has Treated With “Trump Pills” Is Symptom Free In 8-12 Hours!
what does this mean for leronlimab?
go read the old cydy filings and you will probably be very disappointed in cydy mgt
on np's resume it could say: Director of Self-Enrichment from 2012-Current
back to the drawing board for the cydy bod
you are 100% correct
in my opinion, cydy media blitz is to keep cydy stock price as high as possible, it has nothing to do with anything else!